223 related articles for article (PubMed ID: 29044640)
1. A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients.
Domingo C; Pomares X; Navarro A; Amengual MJ; Montón C; Sogo A; Mirapeix RM
Br J Clin Pharmacol; 2018 Feb; 84(2):339-348. PubMed ID: 29044640
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
3. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
5. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.
Kupryś-Lipińska I; Majak P; Molinska J; Kuna P
BMC Pulm Med; 2016 Apr; 16(1):61. PubMed ID: 27117315
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of omalizumab in non-allergic severe asthma.
Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
[TBL] [Abstract][Full Text] [Related]
7. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
8. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
9. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
11. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study.
Domingo C; Mirapeix RM; González-Barcala FJ; Forné C; García F
Drugs; 2023 Aug; 83(12):1111-1123. PubMed ID: 37436680
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
Pelaia G; Gallelli L; Romeo P; Renda T; Busceti MT; Proietto A; Grembiale RD; Marsico SA; Maselli R; Vatrella A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):713-21. PubMed ID: 22122813
[TBL] [Abstract][Full Text] [Related]
14. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
[TBL] [Abstract][Full Text] [Related]
15. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience.
Giubergia V; Ramírez Farías MJ; Pérez V; Crespi N; Castaños C
Arch Argent Pediatr; 2019 Apr; 117(2):e115-e120. PubMed ID: 30869489
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
18. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
19. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
[TBL] [Abstract][Full Text] [Related]
20. Comparison of allergic asthma patients treated with omalizumab and non-allergic patients treated with continuous oral corticosteroids: results of five year follow-up therapies.
Gemicioğlu B; Çalışkaner Öztürk B; Duman B
Tuberk Toraks; 2016 Jun; 64(2):97-104. PubMed ID: 27481075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
